Tele-oncology and the Future of Cancer Care Delivery: A Review of Emerging Models, Rural Applications, and Pharmaceutical Integration

 Dr. Omid Modiramani ^*

 

*Correspondence to:  Dr. Omid Modiramani, MD, Medical Oncologist & Hematologist, Saudi German Hospital, Dubai.

Copyright.

© 2025  Dr. Omid Modiramani This is an open access article distributed under the Creative Commons Attribution   License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Received: 21 Aug 2025

Published: 28 Aug 2025

DOI: https://doi.org/10.5281/zenodo.17284901

 

Abstract

Importance: Teleoncology—the use of telemedicine technologies in oncology—has emerged as a critical tool in addressing cancer care disparities, particularly among rural, underserved, and resource-limited populations. Despite growing adoption, comprehensive synthesis of its implementation, barriers, and future directions remains limited.

Objective: To review the historical evolution, core applications, challenges, and future directions of teleoncology, with emphasis on rural deployment, pharmaceutical industry integration, and implications for equity-based cancer care delivery.

Evidence Review: A narrative review was conducted of literature published between January 2005 and March 2024 using PubMed, Scopus, WHO reports, ASCO resources, and policy documents from oncology organizations and government health agencies. Included sources comprised peer-reviewed studies, white papers, program evaluations, and regulatory frameworks. Key themes were synthesized under domains including access to care, remote treatment monitoring, decentralized trials, patient experience, infrastructure, and stakeholder collaboration.

Findings: Teleoncology has evolved from early second-opinion consults to comprehensive models including remote diagnosis, virtual tumor boards, remote chemotherapy supervision, and digital navigation tools. Rural implementation in the United States has shown significant benefits including reduced travel burden, improved time-to-treatment, and non-inferior survival rates. Globally, countries such as Australia, India, and Kenya have adopted teleoncology to extend services to remote areas. Major pharmaceutical companies now support teleoncology-enabled decentralized clinical trials, AI-powered symptom tracking, and real-world evidence generation. Key barriers to implementation include infrastructure deficits, inconsistent reimbursement, regulatory misalignment, digital literacy gaps, and ethical concerns about data use. Emerging hybrid care models, equity-centered platform design, and global licensing frameworks are shaping the future landscape.

Conclusions and Relevance: Teleoncology is redefining cancer care by enabling more equitable, scalable, and digitally integrated delivery models. As healthcare systems transition to hybrid oncology ecosystems, success will depend on coordinated policy reform, sustained infrastructure investment, and cross-sector partnerships—including pharmaceutical and technology stakeholders. Future models must ensure cultural responsiveness, digital inclusion, and long-term sustainability to fulfill the promise of teleoncology in improving global cancer outcomes.

Implications for Practice and Policy

The expansion of teleoncology has profound implications for the future of cancer care delivery, particularly in addressing geographic and socioeconomic disparities. For clinical practice, it enables oncologists to extend their reach into rural and underserved communities, improving timely access to diagnosis, treatment, and survivorship services. Adoption of virtual tumor boards, remote monitoring tools, and hybrid models allows for continuity of care without compromising clinical outcomes—especially for patients with transportation, mobility, or immunosuppression challenges.

For policymakers, teleoncology highlights the urgent need for standardized reimbursement, cross-state licensure reforms, and investment in digital infrastructure, particularly broadband in rural areas. Equitable access also requires attention to digital literacy programs, language services, and culturally tailored platforms. Regulators and payers should support the integration of teleoncology into value-based oncology payment models and national cancer control plans, ensuring sustainability beyond pilot initiatives.

Strategic alignment between healthcare systems, government agencies, and the pharmaceutical industry is essential to scale teleoncology ethically and effectively. Its success will depend not just on technology, but on policies that prioritize equity, interoperability, and long-term health system resilience.

 

Introduction

Cancer care delivery has traditionally relied on centralized tertiary or academic medical centers, resulting in significant geographic and socioeconomic disparities in access to oncologic services. In the United States alone, nearly 20% of the population resides in rural areas, yet fewer than 5% of oncologists practice in those regions [1]. This maldistribution of the oncology workforce has led to documented delays in diagnosis, limited participation in clinical trials, and worse survival outcomes for rural and underserved populations [2,3].

Teleoncology—a subset of telemedicine specifically applied to cancer diagnosis, treatment planning, symptom management, and follow-up—has emerged as a scalable, technology-enabled strategy to address these inequities. It leverages digital communication tools to connect patients with remote oncologists, enable virtual tumor boards, monitor chemotherapy toxicity, and conduct decentralized clinical trials [4].

The field of teleoncology evolved from early experiments in remote tumor board participation and second-opinion consultations in the early 2000s to comprehensive virtual cancer care ecosystems. These include secure telehealth platforms integrated with electronic health records (EHRs), artificial intelligence (AI)–enabled triage systems, and digital pathology services [5,6]. The COVID-19 pandemic accelerated the adoption of telemedicine in oncology, prompting temporary regulatory waivers, expanded reimbursement from public and private payers, and rapid scaling of infrastructure [7].

As teleoncology becomes embedded in routine practice, it serves as a critical modality for reaching patients in rural U.S. counties (65% of which lack a full-time oncologist) and in low-resource settings globally [8,9]. Moreover, it enables inclusive care models for populations that historically have had poor representation in clinical trials, such as racial and ethnic minorities, the elderly, and geographically isolated groups [10].

This review explores the evolution of teleoncology, its core applications across the cancer care continuum, regional implementation efforts, the role of pharmaceutical industry stakeholders, and future directions in ensuring equitable, innovative cancer care delivery.

 

Historical Development of Teleoncology

The foundation of teleoncology dates back to general telemedicine innovations in the late 1990s and early 2000s. Initially, telemedicine was adopted for urgent care and specialist consultation in remote areas by government agencies such as NASA and the Department of Defense. Oncology-specific applications emerged as cancer centers sought to reach medically underserved populations in rural and frontier regions [11,12].

 

Early Phase (2000–2010):

In this period, teleoncology primarily involved:

• Second-opinion consultations via videoconferencing between tertiary centers and rural clinics.

• Virtual tumor boards, allowing collaborative review of patient cases across institutions.

• Telepathology, enabling digital transmission of histology slides for remote diagnostic input.

 

Programs such as the Queensland Teleoncology Program in Australia pioneered this model to deliver cancer services to Indigenous communities [13]. In the U.S., academic hospitals began partnering with Veterans Affairs (VA) and critical access hospitals to extend services [14].

 

Growth Phase (2011–2019):

This era saw enhanced uptake due to:

• Broadband expansion and federal grants, especially in the U.S. through FCC’s Rural Health Care Program.

• Widespread adoption of electronic health records (EHRs), enabling remote access to labs, imaging, and treatment plans [15].

• Structured clinical workflows, including local nurses or general physicians facilitating video consults with offsite oncologists.

• Pilot programs, such as those in Alaska, Arizona, and Minnesota, which showed improvements in timely care and patient satisfaction [16].

 

Studies from this period demonstrated that teleoncology was non-inferior to in-person visits for treatment decisions, symptom management, and follow-up care, particularly when supported by well-trained local teams [17].

 

COVID-19 Catalysis (2020–2022):

The COVID-19 pandemic acted as a systemic accelerant:

• CMS and other payers implemented temporary waivers allowing cross-state licensure and reimbursed tele-oncology services at parity with in-person care [18].

• Rapid digital infrastructure deployment occurred across academic and private cancer centers.

• Virtual chemotherapy supervision protocols were developed, combining telemedicine visits with remote toxicity monitoring and emergency triage pathways.

• Patient acceptance surged, with up to 87% of patients expressing satisfaction with virtual cancer visits for follow-up, symptom checks, and survivorship care [19, 20].

 

Consolidation and Innovation (2023–Present):

Recent years have seen maturation of teleoncology infrastructure and more sophisticated applications:

• Integration of artificial intelligence (AI) in remote monitoring, predictive analytics, and digital navigation tools [21].

• Pharmaceutical partnerships with oncology centers to deliver decentralized clinical trials using e-consent, home visits, and courier-based drug delivery systems [22].

• Global adaptations, especially in low- and middle-income countries (LMICs), where teleoncology is being used to support screening, triage, and follow-up for breast, cervical, and prostate cancer [23].

 

Emerging innovations also include hybrid models combining asynchronous consultations, wearable devices, and real-time alerts for early detection of complications. These tools are being piloted in rural U.S. states and LMICs, signaling a more inclusive and sustainable oncology future [24].

 

Core Applications of Teleoncology

Teleoncology encompasses a broad spectrum of services beyond video consultations. Its applications are now embedded across various stages of cancer care, including screening, diagnostics, treatment monitoring, clinical trial participation, palliative support, and survivorship. These modalities are not only useful in rural areas but also in urban underserved communities, post-disaster zones, correctional facilities, and low- and middle-income countries (LMICs) [25].

 

1. Remote Consultations

Remote video consultations allow patients to engage with oncologists for diagnosis, treatment planning, and follow-up without the need to travel to specialty centers. These consultations are typically conducted using HIPAA-compliant telehealth platforms integrated with electronic health records (EHRs) [26].

Key benefits:

•  Dec reased patient travel costs and absenteeism from work [27]

• Shorter wait times for initial evaluation [28]

• Greater access to sub-specialists, including medical oncologists, radiation oncologists, and genetic counselors

• Improved coordination between rural primary care physicians and academic centers [29]

A study from the U.S. Veterans Health Administration demonstrated that tele-oncology reduced time to chemotherapy initiation by 26% in rural veterans with newly diagnosed cancer [30].

 

2. Virtual Tumor Boards

Multidisciplinary tumor boards (MTBs) are essential in developing consensus-based treatment plans. Virtual MTBs enable participation by specialists across different institutions—especially helpful when expertise in radiation oncology, pathology, or surgical oncology is not locally available [31].

Functionality includes:

•  Collaborative review of imaging, histopathology, and genomics

•  Shared decision-making with real-time input from tertiary and local providers

•  Ability to include the patient or their local provider in the discussion [32]

Evidence shows that virtual MTBs reduce unnecessary transfers to tertiary centers and increase clinical trial enrollment rates by connecting patients with distant trial sites [33].

 

3. Remote Chemotherapy Monitoring and Symptom Management

Teleoncology supports safe chemotherapy administration in local facilities under virtual supervision. This model is especially effective in rural areas, where trained nursing staff administer therapy while oncologists monitor side effects, manage toxicities, and adjust treatment plans remotely [34].

Technologies used:

•  ePRO (electronic patient-reported outcomes) platforms

•  AI-assisted symptom triage systems

•  Video check-ins before each chemotherapy cycle

•  Wearables to track temperature, blood pressure, oxygen saturation, and fatigue patterns [35]

One program in rural Canada reduced emergency room visits related to chemotherapy toxicity by 37% using telemonitoring tools [36].

 

4. Decentralized Clinical Trials (DCTs)

Teleoncology is revolutionizing trial participation by removing geographic barriers. Pharmaceutical companies and academic centers now leverage telehealth platforms to enroll patients remotely, deliver investigational drugs to homes, and collect data virtually [37].

Features of tele-enabled DCTs:

•  eConsent and remote eligibility screening

•  Courier-based biosample collection

•  Integration of wearable device data and remote lab monitoring

•  Real-time adverse event reporting

The FDA reported a 42% increase in decentralized trial protocols in oncology since 2021, with higher enrollment of rural and minority patients compared to conventional designs [38].

 

5. Psychosocial Support and Palliative Care

Teleoncology allows for the integration of mental health services, spiritual care, and palliative symptom management in both early-stage and terminal cancer care [39].

Applications:

• Virtual counseling for depression, anxiety, and PTSD

• Remote symptom management (e.g., pain, nausea, constipation, breathlessness)

• Virtual family meetings and end-of-life planning

• Bereavement support for caregivers

 

Studies show that virtual palliative care interventions result in higher patient satisfaction and reduced hospital readmissions in the final 30 days of life [40,41].

 

Rural Implementation in the United States

The rural cancer care crisis in the U.S. is one of the most pressing equity issues in oncology. Approximately 60 million Americans live in rural areas, yet 65% of U.S. rural counties have no practicing oncologist, and over 35% lack any type of subspecialist care [42,43]. These geographic disparities contribute to later-stage diagnoses, lower participation in clinical trials, and higher cancer-related mortality [44].

Teleoncology provides a practical solution to these access gaps by enabling virtual oncology services, shared care models, and local chemotherapy administration under remote supervision. Several federal and state-led programs have piloted and scaled teleoncology interventions to support rural populations, especially in Appalachia, the Midwest, and Native American tribal territories [45].

Please view attached pdf to  view complete article